Table 1.
Characteristics of older men in the MrOS cohort by quartiles of pseudo F-statistic (rest-activity rhythm robustness).
| Characteristic | Quartile 1 (8.3 to < 689.6, n = 541) | Quartile 2 (689.6 to < 959.6, n = 587) | Quartile 3 (959.6 to < 1311.9, n = 628) | Quartile 4 (1311.9 to 4501.4, n = 651) | p-Value |
|---|---|---|---|---|---|
| Age (years), mean ± SD | 76.8 ± 5.51 | 75.97 ± 5.34 | 75.53 ± 5.02 | 74.76 ± 4.68 | < 0.001 |
| White race, n (%) | 487 (90.0) | 535 (91.1) | 575 (91.6) | 605 (92.9) | 0.342 |
| Body mass index (kg/m2), mean ± SD | 28.1 ± 4.1 | 27.4 ± 3.7 | 30.0 ± 3.5 | 26.4 ± 3.3 | < 0.001 |
| Urinary melatonina (ng/mg), mean ± SD | 9.7 ± 8.8 | 10.6 ± 8.8 | 11.7 ± 8.8 | 11.4 ± 9.4 | < 0.001 |
| Diabetes, n (%) | 87 (16.1) | 77 (13.1) | 67 (10.7) | 70 (10.8) | 0.016 |
| Heart attack, n (%) | 114 (21.1) | 87 (14.8) | 84 (13.4) | 95 (14.6) | 0.002 |
| Congestive heart failure, n (%) | 51 (9.4) | 25 (4.3) | 30 (4.8) | 22 (3.9) | < 0.001 |
| Hypertension, n (%) | 302 (55.8) | 291 (49.6) | 321 (51.1) | 260 (39.9) | < 0.001 |
| Smoking status, n (%) | 0.192 | ||||
| Never | 212 (39.2) | 248 (42.3) | 255 (40.6) | 254 (39.0) | |
| Past | 310 (57.3) | 330 (56.2) | 364 (58.0) | 383 (58.8) | |
| Current | 19 (3.5) | 9 (1.5) | 9 (1.4) | 14 (2.2) | |
| Drinks per week, n (%) | 0.000 | ||||
| None | 209 (38.9) | 202 (34.7) | 196 (31.3) | 179 (27.6) | |
| 1–13 | 307 (57.1) | 351 (60.2) | 395 (63.1) | 416 (64.2) | |
| 14 + | 22 (4.1) | 30 (5.2) | 35 (5.6) | 53 (8.2) | |
| Caffeine consumption (mg/day), mean ± SD | 215.0 ± 258.4 | 238.0 ± 248.9 | 228.6 ± 235.0 | 261.4 ± 252.1 | 0.001 |
| PASEb score, mean ± SD | 130.2 ± 68.2 | 143.7 ± 68.1 | 156.6 ± 68.8 | 169.6 ± 70.0 | < 0.001 |
| Depression (GDSc > 6), n (%) | 53 (9.8) | 35 (6.0) | 18 (2.9) | 28 (4.3) | < 0.001 |
| Anti-depressant use, n (%) | 41 (7.6) | 47 (8.0) | 39 (6.2) | 40 (6.1) | 0.467 |
| Benzodiazepine use, n (%) | 30 (5.6) | 25 (4.3) | 20 (3.2) | 26 (4.0) | 0.246 |
| Beta blocker use, n (%) | 204 (37.8) | 168 (28.6) | 151 (24.0) | 136 (20.9) | < 0.001 |
| Bisphosphonate use, n (%) | 29 (5.4) | 19 (3.2) | 29 (4.6) | 31 (4.8) | 0.353 |
| Corticosteroid use, n (%) | 54 (10.0) | 51 (8.7) | 61 (9.8) | 55 (8.5) | 0.749 |
| Nocturia, n (%) | 190 (35.12) | 194 (33.05) | 185 (29.46) | 182 (27.96) | 0.031 |
| Serum 25(OH) vitamin D (ng/ml) | 27.98 ± 9.05 | 28.91 ± 8.9 | 29.2 ± 8.86 | 29.97 ± 8.75 | 0.002 |
| Urinary calcium (mg/dl) | 9.08 ± 7.14 | 9.65 ± 6.84 | 9.78 ± 6.94 | 11.12 ± 8.2 | < 0.001 |
p-Values for continuous variables are from ANOVA for normally distributed data; the Kruskal Wallis test was used for skewed data. p-Values for categorical data from a chi-square test.
a
6-Sulfatoxymelatonin (aMT6s), the major urinary metabolite of melatonin.
b
Physical Activity Scale for the Elderly.
c
Geriatric Depression Scale.